A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function
The DOI matches its Crossref record; 245 of the 249 references it cites were found in a registry or an index.
Abstract
Up to 15% of patients with essential hypertension have inappropriate regulation of aldosterone; although only a minority have distinct adrenal tumors, recent evidence shows that mineralocorticoid receptor activation contributes to the age-related blood pressure rise and illustrates the importance of aldosterone in determining cardiovascular risk. Aldosterone also has a major role in progression and outcome of ischemic heart disease. These data highlight the need to understand better the regulation of aldosterone synthesis and its action. Aldosterone effects are mediated mainly through classical nuclear receptors that alter gene transcription. In classic epithelial target tissues, signaling mechanisms are relatively well defined. However, aldosterone has major effects in nonepithelial tissues that include increased synthesis of proinflammatory molecules and reactive oxygen species; it remains unclear how these effects are controlled and how receptor specificity is maintained. Variation in aldosterone production reflects interaction of genetic and environmental factors. Although the environmental factors are well understood, the genetic control of aldosterone synthesis is still the subject of debate. Aldosterone synthase (encoded by the CYP11B2 gene) controls conversion of deoxycorticosterone to aldosterone. Polymorphic variation in CYP11B2 is associated with increased risk of hypertension, but the molecular mechanism that accounts for this is not known. Altered 11beta-hydroxylase efficiency (conversion of deoxycortisol to cortisol) as a consequence of variation in the neighboring gene (CYP11B1) may be important in contributing to altered control of aldosterone synthesis, so that the risk of hypertension may reflect a digenic effect, a concept that is discussed further. There is evidence that a long-term increase in aldosterone production from early life is determined by an interaction of genetic and environmental factors, leading to the eventual phenotypes of aldosterone-associated hypertension and cardiovascular damage in middle age and beyond. The importance of aldosterone has generated interest in its therapeutic modulation. Disadvantages associated with spironolactone (altered libido, gynecomastia) have led to a search for alternative mineralocorticoid receptor antagonists. Of these, eplerenone has been shown to reduce cardiovascular risk after myocardial infarction. The benefits and disadvantages of this therapeutic approach are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Primary aldosteronism (PA) is associated with increased risk for dysglycemia.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [7]
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Frayling, T. M., Timpson, N. J., Weedon, M. N., Zeggini, E., Freathy, R. M., Lindgren, C. M., Perry, J. R. B., Elliott, K. S., Lango, H., Rayner, N. W., et al. (2007) · Science · doi:10.1126/science.1141634 · Cited by 4,531
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
Weber, K. T., & Brilla, C. G. (1991) · Circulation · doi:10.1161/01.cir.83.6.1849 · Cited by 2,027
A Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,009
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987) · Science · doi:10.1126/science.3037703 · Cited by 1,946
Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
Santos, R. A. S., e Silva, A. C. S., Maric, C., Silva, D. M. R., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V. B., Lopes, M. T., Bader, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432869100 · Cited by 1,801
Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones
Payne, A. H., & Hales, D. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0030 · Cited by 1,766
Cited by
Vitamin D status and arterial hypertension: a systematic review
Pilz, S., Tomaschitz, A., Ritz, E., & Pieber, T. R. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.135 · Cited by 406
“Mechanistic links with blood pressure The renin–angiotensin–aldosterone system Increased activation of the renin–angiotensin–aldosterone system (RAAS), which is a main regulator of electrolyte and volume homeostasis, contributes to the development of arterial hypertension”
BackgroundUpdate on tissue renin–angiotensin systems
Bader, M., & Ganten, D. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0336-0 · Cited by 293
“Mineralocorticoid receptor antagonists turned out to decrease the risk after myocardial infarction [59, 60 ].”
BackgroundParthasarathy, H. K., Ménard, J., White, W. B., Young, W. F., Williams, G. H., Williams, B., Ruilope, L. M., McInnes, G. T., Connell, J. M., & MacDonald, T. M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283455ca5 · Cited by 281
Self-citationBlood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis
Burgaz, A., Orsini, N., Larsson, S. C., & Wolk, A. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834320f9 · Cited by 247
Amar, L., Azizi, M., Menard, J., Peyrard, S., Watson, C., & Plouin, P.-F. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.157271 · Cited by 202
Gender Differences in Cardiovascular Disease: Hormonal and Biochemical Influences
Pérez-López, F. R., Larrad-Mur, L., Kallen, A., Chedraui, P., & Taylor, H. S. (2010) · Reproductive Sciences · doi:10.1177/1933719110367829 · Cited by 202
“Aldosteronism is a well-recognized cause of hypertension and also plays a major role in progression and outcome of IHD.177 Aldosterone is regulated by the pituitary-adrenal axis and the RAAS and itself regulates extracellular fluid content and electrolyte balance.”
BackgroundTASK channel deletion in mice causes primary hyperaldosteronism
Davies, L. A., Hu, C., Guagliardo, N. A., Sen, N., Chen, X., Talley, E. M., Carey, R. M., Bayliss, D. A., & Barrett, P. Q. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712000105 · Cited by 198
A Clinical Prediction Score to Diagnose Unilateral Primary Aldosteronism
Küpers, E. M., Amar, L., Raynaud, A., Plouin, P.-F., & Steichen, O. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1917 · Cited by 179
Aldosterone and arterial hypertension
Tomaschitz, A., Pilz, S., Ritz, E., Obermayer-Pietsch, B. M., & Pieber, T. R. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.263 · Cited by 176
“Aldosterone Synthesis The ALDOS protein (cytochrome P450 11B2, mitochondrial, also known as aldosterone synthase) is the key enzyme involved in aldosterone production and its expression is mainly regulated by angiotensin II, potassium and adrenocorticotropic hormone (ACTH; Figure 2 )”
BackgroundEisenhofer, G., Dekkers, T., Peitzsch, M., Dietz, A. S., Bidlingmaier, M., Treitl, M., Williams, T. A., Bornstein, S. R., Haase, M., Rump, L. C., et al. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.251199 · Cited by 158
Charmandari, E., Sertedaki, A., Kino, T., Merakou, C., Hoffman, D. A., Hatch, M. M., Hurt, D. E., Lin, L., Xekouki, P., Stratakis, C. A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1334 · Cited by 131
Stein, E. A., Stroes, E. S. G., Steiner, G. A., Buckley, B. M., Capponi, A. M., Burgess, T., Niesor, E. J., Kallend, D. G., & Kastelein, J. J. P. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.02.061 · Cited by 136
Allosteric Modulators of Steroid Hormone Receptors: Structural Dynamics and Gene Regulation
Kumar, R., & McEwan, I. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1033 · Cited by 135
Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease
Tomaschitz, A., Ritz, E., Pieske, B., Fahrleitner-Pammer, A., Kienreich, K., Horina, J. H., Drechsler, C., Marz, W., Ofner, M., Pieber, T. R., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs092 · Cited by 132
Matrozova, J., Steichen, O., Amar, L., Zacharieva, S., Jeunemaitre, X., & Plouin, P.-F. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.122002 · Cited by 118
Lee, H., Lee, D.-Y., Cho, H., Kim, S.-Y., Iwasaki, Y., & Kim, I. K. (2013) · Circulation Research · doi:10.1161/circresaha.113.301071 · Cited by 121
Krug, A. W., Allenhöfer, L., Monticone, R. E., Spinetti, G., Gekle, M., Wang, M., & Lakatta, E. G. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.148783 · Cited by 122
Glucocorticoid resistance in chronic diseases
Rodriguez, J. M., Monsalves‐Álvarez, M., Henríquez, S., Llanos, M. N., & Troncoso, R. (2016) · Steroids · doi:10.1016/j.steroids.2016.09.010 · Cited by 117
Outcomes of Adrenalectomy in Patients with Unilateral Primary Aldosteronism: A Review
Steichen, O., Zinzindohoué, F., Plouin, P., & Amar, L. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0031-1299681 · Cited by 117
“It is therefore assumed that sustained aldosterone hypersecretion induces t arget organ damage through genomic effects mediated by the mineralocorticoid receptor and possibly also by direct, non genomic effects [3].”
BackgroundAldosterone: A forgotten mediator of the relationship between psychological stress and heart disease
Kubzansky, L. D., & Adler, G. K. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.005 · Cited by 103
Aldosterone synthase inhibition in humans
Azizi, M., Amar, L., & Ménard, J. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs388 · Cited by 112
“The acute and chronic regulation of aldosterone synthesis is mediated principally by angiotensin II, potassium and adrenocorticotropic hormone (ACTH) [3, 24].”
BackgroundInfluentialCorticosteroid receptors, macrophages and cardiovascular disease
Rickard, A. J., & Young, M. J. (2009) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0144 · Cited by 118
“MR antagonists have been shown to be effective anti-hypertensive agents in essential hypertension, suggesting a role for MR signalling in hypertension (Connell et al. 2008).”
BackgroundStructure–function relationships in the mineralocorticoid receptor
Pippal, J. B., & Fuller, P. J. (2008) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0093 · Cited by 101
“2008) and the central nervous systems (CNS; Connell et al. 2008).”
BackgroundInfluentialThe Effects of Vitamin D Deficiency on Atrial Fibrillation
Demir, M., Uyan, U., & Melek, M. (2014) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612453762 · Cited by 95
“It has been demonstrated in the studies conducted that vitamin D deficiency may play a role in the development of autoimmune diseases, inflammatory bowel disease, rheumatoid arthritis, psoriasis, multiple sclerosis, diabetes, certain types of cancer, cardiac failure, stroke, and infectious diseases, such as tuberculos…”
BackgroundSteroidogenesis—Adrenal Cell Signal Transduction
Gallo‐Payet, N., & Battista, M. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130050 · Cited by 74
Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism
Amar, L., Plouin, P.-F., & Steichen, O. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-9 · Cited by 83
“Thus, correcting for aldosterone hypersecretion is a treatment objective per se [65].”
BackgroundIncreased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome
Yiu, K., Marsan, N. A., Delgado, V., Biermasz, N. R., Holman, E. R., Smit, J. W. A., Feelders, R. A., Bax, J. J., & Pereira, A. M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0601 · Cited by 90
Primary Hyperaldosteronism: Expanding the diagnostic net
Djajadiningrat‐Laanen, S. C., Galac, S., & Kooistra, H. S. (2011) · Journal of Feline Medicine and Surgery · doi:10.1016/j.jfms.2011.07.017 · Cited by 94
Spironolactone for hypertension
Batterink, J., Stabler, S. N., Tejani, A. M., & Fowkes, C. T. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008169.pub2 · Cited by 74
Martinerie, L., Munier, M., Menuet, D. L., Méduri, G., Viengchareun, S., & Lombès, M. (2012) · Biochimie · doi:10.1016/j.biochi.2012.09.030 · Cited by 78
Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis
Young, M. J., & Rickard, A. J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.008 · Cited by 77
Pippal, J. B., Yao, Y., Rogerson, F. M., & Fuller, P. J. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0032 · Cited by 66
“The MR plays a critical role in the pathophysiology of hypertension and cardiac dysfunction as well as in neurophysiological dysfunction in humans (6, 7).”
BackgroundFuture of Cholesteryl Ester Transfer Protein Inhibitors
Rader, D. J., & deGoma, E. M. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-163305 · Cited by 66
“Studies of patients with hyperaldosteronism demonstrated an increased risk of a wide array of cardiovascular endpoints, including myocardial infarction, stroke, heart failure, atrial fibrillation, and left ventricular hypertrophy (22, 23).”
Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2
Young, M. J., Clyne, C. D., & Chapman, K. E. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0260 · Cited by 69
The role of radiologic studies in the evaluation and management of primary hyperaldosteronism
White, M. L., Gauger, P. G., Doherty, G. M., Cho, K. J., Thompson, N. W., Hammer, G. D., & Miller, B. S. (2008) · Surgery · doi:10.1016/j.surg.2008.07.025 · Cited by 63
Genomic epidemiology of blood pressure salt sensitivity
Kelly, T. N., & He, J. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283524949 · Cited by 61
“Angiotensin II raises BP by direct vasoconstriction, increasing both sympathetic nerve activity and myocardial contractility [27].”
BackgroundAssociation of plasma aldosterone with the metabolic syndrome in two German populations
Hannemann, A., Meisinger, C., Bidlingmaier, M., Döring, A., Thorand, B., Heier, M., Belcredi, P., Ladwig, K.-H., Wallaschofski, H., Friedrich, N., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1074 · Cited by 57
Häfner, S., Baumert, J. J., Emeny, R. T., Lacruz, M. E., Bidlingmaier, M., Reincke, M., Kuenzel, H., Holle, R., Rupprecht, R., & Ladwig, K. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.06.007 · Cited by 63
“Aldosterone is known to promote cardiovascular injury (Connell et al., 2008) and endothelial dysfunction (Sowers et al.”
BackgroundAldosterone/Renin Ratio Determines Peripheral and Central Blood Pressure Values Over a Broad Range
Tomaschitz, A., März, W., Pilz, S., Ritz, E., Scharnagl, H., Renner, W., Boehm, B. O., Fahrleitner‐Pammer, A., Weihrauch, G., & Dobnig, H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.032 · Cited by 58
Cardiovascular Risk in Primary Hyperaldosteronism
Warchoł-Celińska, E., Lenders, J. W. M., Januszewicz, A., & Prejbisz, A. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1565124 · Cited by 59
Chen, W., Li, F., He, C., Zhu, Y., & Tan, W. (2014) · Irish Journal of Medical Science · doi:10.1007/s11845-013-1007-x · Cited by 53
“Recently, a number of clinical and experimental studies indicated that PA is associated with metabolic syndrome [2, 3], especially with the altered glucose metabolism and cardiovascular events.”
BackgroundNogueira, E. F., Gerry, D., Mantero, F., Mariniello, B., & Rainey, W. E. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03738.x · Cited by 51
Management of hypertension in primary aldosteronism
Aronova, A., Fahey, T. J., & Zarnegar, R. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i5.227 · Cited by 59
Martínez‐Aguayo, A., Marlene Aglony, I., Campino, C., García, H., Bancalari, R. E., Bolte, L., Avalos, C., Loureiro, C., Carvajal, C. A., Ávila, A., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.155135 · Cited by 48
Aldosterone to Renin Ratio – A Reliable Screening Tool for Primary Aldosteronism?
Tomaschitz, A., & Pilz, S. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1248326 · Cited by 47
Miller, B. S., Turcu, A. F., Nanba, A. T., Hughes, D. T., Cohen, M. S., Gauger, P. G., & Auchus, R. J. (2017) · World Journal of Surgery · doi:10.1007/s00268-017-4311-1 · Cited by 47
Reducing dietary sodium intake: the Canadian context
Barr, S. I. (2010) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h09-126 · Cited by 54
Cornu, E., Steichen, O., Nogueira‐Silva, L., Küpers, E. M., Pagny, J.-Y., Grataloup, C., Baron, S., Zinzindohoué, F., Plouin, P., & Amar, L. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07214 · Cited by 50
“Its prevalence ranges from 5% to 10% among hypertensive patients.(2) It can be caused by unilateral or bilateral disease.”
BackgroundReynolds, R. M., Walker, B. R., Phillips, D. I., Dennison, E. M., Fraser, R., Mackenzie, S. M., Davies, E., & Connell, J. M. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.129320 · Cited by 47
Self-citationAldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases
Azizi, M., Mallart-Riancho, J., & Amar, L. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae823 · Cited by 47
Primary Aldosteronism and Obstructive Sleep Apnea: Is This A Bidirectional Relationship?
Prejbisz, A., Kołodziejczyk‐Kruk, S., Lenders, J. W. M., & Januszewicz, A. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-122887 · Cited by 45
Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism
Lin, X., Ullah, M. H. E., Xiong, W., Xu, F., Shan, S., Lei, L.-M., Yuan, L., & Liu, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.798364 · Cited by 45
Progress in Primary Aldosteronism: Present Challenges and Perspectives
Gómez-Sánchez, C. E., Rossi, G. P., Fallo, F., & Mannelli, M. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0029-1243619 · Cited by 43
“When first described, PA was equated to an APA that could be surgically cured [47, 48].”
BackgroundFamilial and Phenotypic Associations of the Aldosterone Renin Ratio
Alvarez‐Madrazo, S., Padmanabhan, S., Mayosi, B. M., Watkins, H. C., Avery, P. J., Wallace, A. M., Fraser, R., Davies, E., Keavney, B. D., & Connell, J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1406 · Cited by 44
“It is necessary, in interpreting the ARR, to be aware of the physiological factors and the familial and genetic variables that contribute to the short- and long-term control of renin and aldosterone secretion (1, 11, 12).”
BackgroundMethodSelf-citationvan der Linden, P., Steichen, O., Zinzindohoué, F., & Plouin, P. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e328350225d · Cited by 46
“In patients undergoing surgery for primary aldosteronism, the mean decrease in BP is generally large and linked to a decrease in aldosterone hypersecretion that may confer additional cardiovascular and renal protection [7].”
BackgroundPrimary Hyperaldosteronism in Cats
Kooistra, H. S. (2020) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2020.05.007 · Cited by 45
Pharmacological treatment of aldosterone excess
Deinum, J., Riksen, N. P., & Lenders, J. W. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.006 · Cited by 45
Alvarez‐Madrazo, S., MacKenzie, S. M., Davies, E., Fraser, R., Lee, W.-K., Mj, B., Caulfield, M. J., Dominiczak, A. F., Farrall, M., Lathrop, M. G., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.200741 · Cited by 42
“These findings are also consistent with the known association between SNPs in the 5′ regulatory region of CYP11B1 and minor impairment of 11β-hydroxylation efficiency(14); the relevance of this to the long-term risk of hypertension has been the subject of a detailed review elsewhere.(27) We do not have data on circula…”
ResultSelf-citationAnalysis of Insulin Sensitivity in Adipose Tissue of Patients with Primary Aldosteronism
Urbanet, R., Pilon, C., Calcagno, A., Peschechera, A., Hubert, E.-L., Giacchetti, G., Gomez-Sanchez, C., Mulatero, P., Toffanin, M., Sonino, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0097 · Cited by 38
“Aldosterone excess in primary aldosteronism is related to impaired glucose homeostasis and insulin resistance, leading to increased prevalence of metabolic syndrome (1–3) and a high rate of cardiovascular events (4).”
BackgroundAmar, L., Azizi, M., Ménard, J., Peyrard, S., & Plouin, P. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835d6d49 · Cited by 38
“This approach aims to decrease plasma aldosterone concentrations by inhibiting its production in adrenal glands and in tissues in which extra-adrenal synthesis is thought to occur [1].”
BackgroundVitamin D Deficiency and Cardiovascular Diseases
Jorge, A. J. L., Cordeiro, J. R., Rosa, M. L. G., & Bianchi, D. B. C. (2018) · International Journal of Cardiovascular Sciences · doi:10.5935/2359-4802.20180025 · Cited by 49
Cai, X., Song, S., Hu, J., Zhu, Q., Shen, D., Yang, W., Ma, H., Luo, Q., Hong, J., Zhang, D., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54971-4 · Cited by 33
Sypniewska, G., Pollak, J., Stróżecki, P., Camil, F., Kretowicz, M., Janikowski, G., Mańkowska‐Cyl, A., Pater, A., & Manitius, J. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hpt174 · Cited by 33
Primary Aldosteronism: Results of Adrenalectomy for Nonsingle Adenoma
Quillo, A. R., Grant, C. S., Thompson, G. B., Farley, D. R., Richards, M. L., & Young, W. F. (2011) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2011.03.007 · Cited by 35
“The risks continue: more marked left ventricular hypertrophy, diastolic dysfunction, and alterations in left ventricular filling(4); increased arterial stiffness(27); and even increased synthesis of proinflammatory molecules and reactive oxygen species.(28) Reversal of renal dysfunction owing to elevated ldosterone ha…”
BackgroundAldosteronoma resolution score predicts long-term resolution of hypertension
Aronova, A., Gordon, B. L., Finnerty, B. M., Zarnegar, R., & Fahey, T. J. (2014) · Surgery · doi:10.1016/j.surg.2014.08.019 · Cited by 33
Age‐ and sex‐specific reference ranges are needed for the aldosterone/renin ratio
Solanki, P., Gwini, S. M., Doery, J. C. G., Choy, K. W., Shen, J., Young, M. J., Fuller, P. J., & Yang, J. (2020) · Clinical Endocrinology · doi:10.1111/cen.14199 · Cited by 31
Hypertension, Insulin Resistance, and Aldosterone: Sex‐Specific Relationships
Kidambi, S., Kotchen, J. M., Krishnaswami, S., Grim, C. E., & Kotchen, T. A. (2009) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2009.00084.x · Cited by 31
Carter, Y. M., Roy, M., Sippel, R. S., & Chen, H. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.07.059 · Cited by 32
“[17] Connell JMC, MacKenzie SM, Freel EM, Fraser R, Davies E.”
BackgroundSalt Sensitivity: Challenging and Controversial Phenotype of Primary Hypertension
Iatrino, R., Manunta, P., & Zagato, L. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0677-y · Cited by 30
Al‐Dujaili, E. A. S., Mullins, L. J., Bailey, M. A., Andrew, R., & Kenyon, C. J. (2009) · Steroids · doi:10.1016/j.steroids.2009.06.009 · Cited by 27
Captopril suppression: limitations for confirmation of primary aldosteronism
Westerdahl, C., Bergenfelz, A. O. J., Isaksson, A., & Valdemarsson, S. V. (2011) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320310390405 · Cited by 30
Chiari–like malformation and syringomyelia
Rusbridge, C. (2014) · Surrey Research Insight Open Access (The University of Surrey) · Cited by 27
Pilz, S., Tomaschitz, A., Stepan, V. M., Obermayer-Pietsch, B. M., Fahrleitner‐Pammer, A., Schweighofer, N., Portugaller, H. R., Sourij, H., Dobnig, H., Meinitzer, A., et al. (2009) · BMC Endocrine Disorders · doi:10.1186/1472-6823-9-11 · Cited by 28
“It should, however, be pointed out that the regulation of aldosterone secretion is a complex process with many influence factors that still need to be further explored in detail [35].”
BackgroundFamilial or Genetic Primary Aldosteronism and Gordon Syndrome
Stowasser, M., Pimenta, E., & Gordon, R. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.01.007 · Cited by 26
Mutations in KCNJ5 determines presentation and likelihood of cure in primary hyperaldosteronism
Ip, J. C. Y., Pang, T., Pon, C. K., Zhao, J., Sywak, M. S., Gill, A. J., Soon, P., & Sidhu, S. B. (2013) · ANZ Journal of Surgery · doi:10.1111/ans.12470 · Cited by 30
“Cycling conditions were as previously described with an annealing temperature of 58°C.(4,6,12,20) The DNA was then purified using the DNAClean and Concentrator kit (Zymo Research, Irvine, CA, USA).”
MethodLu, J., Wang, H., Ahmad, M., Keshtkar‐Jahromi, M., Blaustein, M. P., Hamlyn, J. M., & Leenen, F. H. H. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx214 · Cited by 25
Awasthi, R., Manger, P. T., & Khare, R. K. (2023) · Clinical Hypertension · doi:10.1186/s40885-022-00229-y · Cited by 24
“Renin is primarily produced by the kidney’s juxtaglomerular cells and stimulates the production of angiotensin II and aldosterone, both of which increase BP directly through vasoconstriction and indirectly through salt and water retention and other mechanisms [18].”
BackgroundAldosterone and cardiovascular risk
Vogt, B., & Burnier, M. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0076-8 · Cited by 24
Castro, M. A., Ruiz-Sánchez, J. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Aguilera-Saborido, A., Cerezo, J. F. G., Lazareno, N. L., Quesada, M. E. T., Ramos, J. G., Oriola, J., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03751-1 · Cited by 25
“” In 2008, Connell et al considered that the majority of subjects with an elevated ARR will have an excess of adrenal aldosterone production [106].”
Antihypertensive Role of Tissue Kallikrein in Hyperaldosteronism in the Mouse
Waeckel, L., Potier, L., Chollet, C., Taveau, C., Bruneval, P., Roussel, R., Alhenc‐Gelas, F., & Bouby, N. (2012) · Endocrinology · doi:10.1210/en.2012-1225 · Cited by 21
Mineralocorticoid receptor actions in cardiovascular development and disease
Young, M. J., & Clyne, C. D. (2021) · Essays in Biochemistry · doi:10.1042/ebc20210006 · Cited by 21
Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism
Grewal, S., Fosam, A., Chalk, L., Deven, A., Suzuki, M., Correa, R. R., Blau, J. E., Demidowich, A. P., Stratakis, C. A., & Muniyappa, R. (2021) · Endocrine · doi:10.1007/s12020-020-02576-y · Cited by 20
Monge, M., Lorthioir, A., Bobrie, G., & Azizi, M. (2013) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313513408 · Cited by 20
Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment
Giacchetti, G., Turchi, F., Boscaro, M., & Ronconi, V. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109787455716 · Cited by 24
Renin–angiotensin system blockade: Finerenone
Ruilope, L. M., & Tamargo, J. L. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.02.003 · Cited by 21
Diagnosing endocrine hypertension: a practical approach
Yang, J., Shen, J., & Fuller, P. J. (2017) · Nephrology · doi:10.1111/nep.13078 · Cited by 22
“The main effects of aldosterone are mediated by the mineralocorticoid receptor (MR) in the epithelial cells of the renal collecting duct.(9) MR activation promotes sodium reabsorption, mainly via the epithelial sodium channel, and potassium excretion via NaK-ATPase.”
BackgroundSertedaki, A., Markou, Α., Vlachakis, D., Κοσσίδα, Σ., Campanac, E., Hoffman, D. A., Sierra, M. D. L. L., Xekouki, P., Stratakis, C. A., Kaltsas, G., et al. (2016) · Clinical Endocrinology · doi:10.1111/cen.13132 · Cited by 19
Chen, H.-Y., Lien, Y., & Huang, H. (2014) · Acta veterinaria Scandinavica · doi:10.1186/s13028-014-0088-5 · Cited by 18
“In response to stimulation of the renin-angiotensin system and mineralocorticoid and glucocorticoid receptors of myocytes, development of systemic hypertension, left ventricular hypertrophy (LVH), and myocardial fibrosis are commonly observed in human patients with HAC [1-3].”
BackgroundAmar, L., Lorthioir, A., Azizi, M., & Plouin, P. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0585 · Cited by 17
Mark, P. B., Boyle, S., Zimmerli, L., McQuarrie, E. P., Delles, C., & Freel, E. M. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.70 · Cited by 18
Self-citationPollard, C. M., Ghandour, J., Cora, N., Perez, A., Parker, B. M., Desimine, V. L., Wertz, S. L., Pereyra, J. M., Ferraino, K. E., Patel, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020574 · Cited by 16
“Based o our present findings, ad nal GRK2 upregulation could also very wel le d to the e evated circulati g aldo terone l vels that are likewise known to accompany nd complicate human chronic heart failure [2,3,5,17,27].”
BackgroundLanzani, C. L., Gatti, G., Citterio, L., Messaggio, E., Carpini, S. D., Simonini, M., Casamassima, N., Zagato, L., Brioni, E., Hamlyn, J. M., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06415 · Cited by 15
Seok, Y. M., Lee, H. A., Park, K. M., Hwangbo, M.-H., & Kim, I. K. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1246-2 · Cited by 15
Future pharmacological therapy in hypertension
Stewart, M. H., Lavie, C. J., & Ventura, H. O. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000529 · Cited by 15
Carvajal, C. A., Tapia-Castillo, A., Pérez, J. A., & Fardella, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.768734 · Cited by 14
“5-1255] LCN2 (ng/ml) 96 [61-117] 104 [88-133] 123 [80-131] LCN2-MMP9 (ng/ml) 28 [16-43] 45 [29-65] 52 [29-75] Total LCN2 (ng/ml) 107 [81-162] 179 [156-202] 190 [172-214]”
Chiou, T. T., Chiang, P., Fuh, M., Liu, R., Lee, W.-C., Lee, W., Ng, H., Tsai, Y., Chuang, F.-R., Huang, C., et al. (2009) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.218.17 · Cited by 15
“In addition to hypertension, growing literatures have recognized the important role of aldosterone in end organ damage, including heart, kidney and brain (Connell et al. 2008; Rayner 2008).”
BackgroundVamsi, U. M., Nagalingam, S., Gunda, P., Vishnupriya, S., & Tirunilai, P. (2016) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2016.1200595 · Cited by 16
“The promoter C-344T polymorphism has been reported to be associated with serum aldosterone level and its production (11), blood pressure (12,13), urinary”
BackgroundMopidevi, B., Kaw, M., Puri, N., Ponnala, M., Jain, S., Rana, A., Keetha, N. R., Khuder, S., Fiering, S., & Kumar, A. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000694 · Cited by 13
“Many of the long-term structural and functional effects of aldosterone are attributed to the activation of these mediators.(24) Contextually, higher CYP11B2 expression in transgenic mice with Hap-I is accompanied by upregulation of these inflammatory, adhesion, and redox markers.”
BackgroundSpironolactone for hypertension
Tejani, A. M., Fowkes, C. T., & Batterink, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008169 · Cited by 12
Maria, R. D., Landolina, M., Gasparini, M., Schmitz, B., Campolo, J., Parolini, M., Sanzo, A., Galimberti, P., Bianchi, M., Brand, S.-M., et al. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2012.07.008 · Cited by 11
Metadata
- Authors
- Connell, J. M. C., MacKenzie, S. M., Freel, E. M., Fraser, R., & Davies, E.
- Affiliations
- British Heart Foundation (GB)
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2008-02-21
- Volume
- 29
- Issue
- 2
- Pages
- 133-154
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W1977973738
- Semantic Scholar
- a5e9ead66dd474017e77ece0053f5ef285c2b773
- Cited by
- 182
- References
- 249
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 10 · 2023: 7 · 2022: 4 · 2021: 7 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 10 · 2016: 13 · 2015: 5 · 2014: 13 · 2013: 11 · 2012: 20
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- aldosterone excess, essential hypertension, mineralocorticoid receptor, cardiovascular risk, aldosterone synthase, CYP11B2, CYP11B1, 11β-hydroxylase, ischemic heart disease, proinflammatory molecules, reactive oxygen species, genetic and environmental factors, spironolactone, eplerenone, mineralocorticoid receptor antagonists, myocardial infarction
- MeSH terms
- Aldosterone, Animals, Cardiovascular Physiological Phenomena, Humans, Hyperaldosteronism, Hypertension, Renal, Renin-Angiotensin System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.